This brand name is authorized in Austria, Canada, Estonia, Spain, Finland, Lithuania, Mexico, Poland, United Kingdom
The drug ACTIKERALL contains a combination of these active pharmaceutical ingredients (APIs):
1
Fluorouracil
UNII U3P01618RT - FLUOROURACIL
|
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine – which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the “S” phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid. |
2
Salicylic acid
UNII O414PZ4LPZ - SALICYLIC ACID
|
Salicylic acid has bacteriostatic and fungicidal actions, but it is its keratolytic properties which are important for this medicinal product. When applied externally it produces slow and painless destruction of the epithelium. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
ACTIKERALL Cutaneous solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L01BC52 | Fluorouracil, combinations | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: CA | Health Products and Food Branch | Identifier(s): 02428946 |
Country: EE | Ravimiamet | Identifier(s): 1552014, 1848731 |
Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 77675 |
Country: FI | Lääkealan turvallisuus- ja kehittämiskeskus | Identifier(s): 599927 |
Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 191861 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1064301 |
Country: MX | Comisión Federal para la Protección contra Riesgos Sanitarios | Identifier(s): 233M2012 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100280775 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.